Nippon India Nifty Pharma ETF · Regular · Growth
NAV
₹27.2805
as of 31 Jul 2026
Expense Ratio
—
see scheme documents
AUM
₹1,458 Cr
Lumpsum returns (CAGR)
- 1Y
- +16.95%
- 3Y
- +21.46%
- 5Y
- +13.55%
- Since Inception
- +13.42%
SIP returns (XIRR)
- 1Y
- +31.40%
- 3Y
- +19.45%
- 5Y
- +19.17%
- Since Inception
- +19.17%
What history actually did — last 5 years (Aug 2021 – Jul 2026)
A ₹5,000 monthly SIP for the last 5 years (Aug 2021 – Jul 2026)
Real NAV backtest
A ₹5,000 monthly SIP would be worth ₹4,74,194 today — ₹2,95,000 invested, 19.6% XIRR.
₹2,95,000
Invested
₹4,74,194
Value today
19.6%
XIRR (p.a.)
A ₹1,00,000 lumpsum, the last 5 years (Aug 2021 – Jul 2026)
Real NAV backtest
₹1,00,000 invested 5 years ago would be ₹1,88,166 today (13.5% CAGR).
A regular withdrawal plan (SWP)
Real NAV backtest
A ₹10,00,000 corpus withdrawing ₹5,000/month since Aug 2021 would still hold ₹14,07,467.
Buying the worst day
Real NAV backtest
₹1,00,000 invested on the worst market day of the last 5 years (Aug 2021 – Jul 2026) (3 Jun 2024) would be ₹1,42,244 today (1.42×).
Historical simulation using actual published NAVs for the stated period. Past performance may or may not be sustained in the future. Not investment advice.
Risk Metrics
Trailing 1 year, annualised0.52
Sharpe Ratio
—
Alpha
—
Beta
0.51
Sortino
15.50%
Std Dev
-10.23%
Max Drawdown
Performance Comparison
Thinking about Nippon India Nifty Pharma ETF · Regular · Growth?
Talk to our AMFI-registered team — free, no pressure. We'll help you see if this fund fits your goals.
Fund Details
Available transactions
Investment Objective
Nippon India Nifty Pharma ETF · Regular · Growth is an exchange-traded fund (ETF) that trades on stock exchanges like a regular share. It offers real-time pricing, low expense ratios, and the flexibility to buy and sell units throughout the trading day.
About This Fund
Nippon India Nifty Pharma ETF · Regular · Growth is a ETF mutual fund offered by Nippon India Mutual Fund. The fund has been operational for over 5 years. It manages assets worth ₹1,458 Cr, reflecting investor confidence in the fund's strategy. It benchmarks its performance against NIFTY PHARMA TRI.
Who Should Invest?
- •Investors with a high risk appetite seeking long-term wealth creation
- •Investors with an investment horizon of 5 years or more
- •Cost-conscious investors who prefer passive investing with low expense ratios
- •SIP investors who can benefit from rupee cost averaging during market fluctuations